On February 6, 2024, Corina® Intrauterine Drug-Eluting Stent, independently designed and developed by Yipurun (Shanghai) Biotechnology Co., Ltd., received its market approval from the Singapore Health Sciences Authority (HSA).
In late April 2025, at the Global Congress on Endometriosis and Uterine Diseases (SEUD) held in Prague, Czech Republic, Professor Feng Limin from the Department of Obstetrics and Gynecology, Beijing Tiantan Hospital, Capital Medical University, presented the core clinical technology behind Corina® (Intrauterine Drug Eluting Stent) to an international audience of gynecology specialists.
In April 2025, Professor Zhang Luping from the Department of Obstetrics and Gynecology, Beijing Tiantan Hospital, Capital Medical University, was invited to speak at the World Congress of the International Federation of Fertility Societies (IFFS) held in Tokyo, Japan.
In October 2025, at the 34th Annual Meeting of the European Society of Gynaecological Endoscopy (ESGE), Professor Feng Limin from Beijing Tiantan Hospital, Capital Medical University, presented extensive real-world clinical data on the application of Corina® (Intrauterine Drug Eluting Stent) based on a large number of cases from China.
Topical drug delivery : Immediate postoperative anti-inflammatory treatment in CRS , ECRS , CA , EN-DCR et al.
Topical high dose steroid-eluting stent : Safety. Precision. Continuation. Efficacy.
enquiry@yipurunbio.com commercial@yipurunbio.com
Room 2206, No. 396, Lishizhen Road, Pudong New Area, Shanghai
